Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26119269 | 1.00 | TLR2 (0.55) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL17747057 | 0.94 | TLR2 (0.54) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL17747059 | 0.94 | TLR2 (0.54) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL26512963 | 0.93 | KMT2A (0.55) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL26513095 | 0.93 | KMT2A (0.55) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL26512989 | 0.93 | KMT2A (0.55) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL17747016 | 0.93 | KMT2A (0.55) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL30608472 | 0.93 | KMT2A (0.55) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL17747013 | 0.93 | KMT2A (0.55) | TLR2MDM2KMT2AMDM4TP53 | |
| SCHEMBL26512797 | 0.91 | TLR2 (0.56) | TLR2MDM2KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | TLR2 121/4885MDM2 757/4885KMT2A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.